urofollitropin

(redirected from Follistim)

urofollitropin

 [u″ro-fol´ĭ-tro″pin]
a preparation of gonadotropins from the urine of postmenopausal women; it contains follicle-stimulating hormone and is used in conjunction with human chorionic gonadotropin to induce ovulation in the treatment of female infertility and to stimulate multiple oocyte development in ovulatory patients utilizing assisted reproductive technologies. Administered by subcutaneous injection.

ur·o·fol·li·tro·pin

(yūr'ō-fol'i-trō'pin),
A preparation of gonadotropin extracted from the urine of postmenopausal women, used in conjunction with human chorionic gonadotropin to induce ovulation.
See also: menotropins.

urofollitropin

/uro·fol·li·tro·pin/ (-fol´ĭ-tro″pin) a preparation of gonadotropins from the urine of postmenopausal women, containing follicle-stimulating hormone and used in conjunction with human chorionic gonadotropin to induce ovulation.

urofollitropin

[u′rofol′itro′pin]
a preparation of gonadotropins from the urine of postmenopausal women. It contains follicle-stimulating hormone and is used in conjunction with human chorionic gonadotropin to induce ovulation in the treatment of female infertility and to stimulate multiple oocyte development in ovulatory patients using assisted reproductive technologies. Administered by subcutaneous injection.

Bravelle

A lyophilised formulation of follicle-stimulating hormone purified from the urine of postmenopausal women, which is used to induce ovulation and as part of the regimen for assisted reproductive technologies—e.g., in vitro fertilisation.

Contraindications Bravelle
• High FSH level indicating primary ovarian failure;
• Uncontrolled thyroid and adrenal dysfunction;
• An organic intracranial lesion—especially pituitary tumours;
• Any cause of infertility other than anovulation;
• Abnormal bleeding of undetermined origin;
• Ovarian cysts or enlargement not due to polycystic ovary syndrome;
• Prior hypersensitivity to urofollitropins, purified;
• Pregnancy.

u·ro·fol·li·tro·pin

(yūr'ō-fol'i-trō'pin)
A preparation of gonadotropin extracted from the urine of postmenopausal women, used in conjunction with human chorionic gonadotropin to induce ovulation.
See also: menotropins
References in periodicals archive ?
The infertility drugs market is analyzed based on the big seven brands (by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn.
Concurrent Antagon[TM] and Follistim therapy for ovulation induction in women with polycystic ovary syndrome (PCOS).
Tokyo, Japan, Aug 8, 2005 - (JCNN) - Nippon Organon will launch Follistim 75 and Follistim 150, its proprietary recombinant follicle stimulating hormone (FSH) products used in assisted reproductive treatment, on August 11.
The Food and Drug Administration has approved the Follistim AQ Cartridge (follitropin beta injection).
This report includes market analysis for seven major (by sales) branded formulations of infertility drugs, namely, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn.
The discount card can be used on all manufacturer brand drugs, including MENOPUR[R], Follistim, Gonal-f[R], and dozens of other generic and name brands.
CHAPTER 5 METHODS OF TREATMENT 63 FERTILITY PHARMACEUTICALS 63 INTRODUCTION AND TYPES 63 Antagon 64 Bravelle 65 Cetrotide 65 Clomid 65 Crinone and Prometrium 66 Fertinex 67 Follistim 67 Gonal-F 67 Humegon 68 Lupron 68 Novarel 68 Ovidrel 69 Parlodel 69 Pregnyl 69 Profasi 69 Prometrium 69 Repronex 69 Serophene 70 TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS 70 MARKET REVENUES AND FORECAST 71 TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.
31, 2007, include $57 million for FOLLISTIM, a fertility treatment, and
The global human reproductive technologies market is categorized into the following segments: Human Reproductive Technologies Market, by Infertility Drugs Gonal-f (recombinant follitropin alfa) Follistim AQ (follitropin beta) AndroGel (testosterone) Testim (testosterone) Viagra (sildenafil citrate) Cialis (tadalafil) Levitra/Staxyn (vardenafil)
31, 2007, include $57 million for FOLLISTIM, a fertility treatment, and $45 million for NUVARING, a contraceptive product.